FY2025 EPS Estimates for Annexon Decreased by HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – HC Wainwright decreased their FY2025 earnings per share estimates for Annexon in a report released on Wednesday, November 12th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of ($1.42) for the year, down from their prior estimate of ($1.34). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s Q4 2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($0.04) EPS.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a report on Wednesday, October 8th. Zacks Research raised shares of Annexon from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Annexon currently has a consensus rating of “Hold” and a consensus target price of $12.50.

Annexon Stock Up 1.1%

ANNX opened at $2.71 on Friday. The firm has a market capitalization of $297.79 million, a P/E ratio of -2.10 and a beta of 1.28. The firm’s 50 day moving average is $2.95 and its 200-day moving average is $2.52. Annexon has a 52-week low of $1.28 and a 52-week high of $6.49.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03).

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its holdings in shares of Annexon by 25.2% in the 1st quarter. Bank of New York Mellon Corp now owns 288,698 shares of the company’s stock valued at $557,000 after acquiring an additional 58,152 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Annexon in the first quarter valued at approximately $127,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Annexon by 164.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company’s stock valued at $66,000 after buying an additional 21,143 shares during the last quarter. XTX Topco Ltd raised its holdings in shares of Annexon by 65.4% during the first quarter. XTX Topco Ltd now owns 58,130 shares of the company’s stock valued at $112,000 after buying an additional 22,979 shares during the last quarter. Finally, J. Safra Sarasin Holding AG boosted its position in shares of Annexon by 63.4% during the first quarter. J. Safra Sarasin Holding AG now owns 254,538 shares of the company’s stock worth $491,000 after buying an additional 98,794 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.